| 近５年杭州地区肝病患者产ESBLs大肠杆菌连续性耐药分析 |
| 投稿时间：2010-09-20 修订日期：2011-08-22 点此下载全文 |
| 引用本文：周俊,宋超,朱明利,厉小玉,章松平.近５年杭州地区肝病患者产ESBLs大肠杆菌连续性耐药分析[J].医学研究杂志,2011,40(9):123-125 |
| DOI：
|
| 摘要点击次数: 1118 |
| 全文下载次数: 1101 |
|
|
| 中文摘要:目的动态观察分析5年杭州地区肝病患者感染产超广谱β-内酰胺酶（ESBLs）大肠杆菌的检出率及耐药性变化，并了解地区总体情况，为临床抗菌治疗提供依据。方法选取从2005年1月~2009年12月入院肝病患者中分离出的非肠道致病性大肠杆菌729株，采用美国临床实验室标准化委员会（NCCLS/CLSI）推荐的纸片扩散确证法进行检测，应用WHONET 5.3软件对药敏试验进行统计，对产ESBLs菌和非产ESBLs菌的药敏试验数据进行对比分析，并对产ESBLs菌的检出率、耐药率以及与杭州综合性医院差异性等方面进行分析。结果5年来杭州地区肝病患者分离出的非肠道致病性大肠杆菌中ESBLs阳性率分别为12.0%、22.0%、21.8%、22.9%和30.3%，呈逐渐上升趋势，但总体低于杭州医院平均水平。除亚胺培南外，产ESBLs菌对抗菌药物的耐药率明显高于非产ESBLs菌，大肠杆菌的耐药率与杭州地区总体情况基本一致。结论肝病患者中大肠杆菌产ESBLs菌的检出率呈逐年上升趋势。亚胺培南、头孢西丁、阿米卡星、哌拉西林/他唑巴坦对肝病患者的产ESBLs大肠杆菌有相对较好的抗菌活性，同时在选用抗菌药物时，除考虑肝功能外，目前对肝病患者可暂不做区别对待。 |
| 中文关键词:肝病 大肠杆菌 ESBLs 耐药性 |
| |
| Dynamic Observation and Analysis of Antibiotic Resistance of ESBLs-producing Escherichia Coli Isolated from Hepatopathy Patients in Hang Zhou Area During the Last 5 Years |
|
|
| Abstract:ObjectiveTo investigate and analyze the isolation rate and antibiotic resistance rate of extended spectrum beta-lactamases (ESBLs)-producing Escherichia coli from hepatopathy patients from 2005 to 2009 and to provide proposals to clinical treatment.Methods729 ESBLs-producing Escherichia coli strains from hepatopathy patients were detected by the method recommended by National Committee for Clinical Laboratory Standards or Clinical and Laboratory Standards Institute (NCCLS/CLSI).The antibiotic susceptibility was tested by the Kirby-Bauer method and the data were analyzed by the software of WHONET5.3.The antibiotic susceptibility test data in either ESBLs-producing or non-producing strains were analyzed comparatively.The isolation rate,antibiotic resistance rate and the differences from other hospitals in the same areas were all analyzed deeply.ResultsOf 729 strains of Escherichia coli,169 strains were positive,with the rate of 12.0%,22.0%,21.8%,22.9% and 30.3% year by year,and the elevating mode by years was shown.The antibiotic susceptibility tests in vitro showed that imipenem,cefoxitin,amikacin and piperacillin-tazobactam were effective to ESBLs-producing Escherichia coli.The ESBLs-producing Escherichia coli displayed the multi-antibiotic resistance,and the drug resistance rate in ESBLs-producing strains was higher than that in non-producing strains.ConclusionThe positive rate of ESBLs-producing Escherichia coli increased year by year in hepatopathy patients during the last five years.Imipenem,cefoxitin,amikacin and piperacillin/tazobactam are suitable for clinical treatment of infection caused by ESBLs-producing Escherichia coli.It is necessary to increase the laboratory detection rates to avoid the drug abuses.The antibiotic drugs used in clinical treatments to hepatopathy patients can be the same as other patients. |
| keywords:Escherichia coli Hepatopathy Extended spectrum beta-lactamases Antibiotic |
| 查看全文 查看/发表评论 下载PDF阅读器 |
|
|
|
